Related Experiment Video
Updated: Feb 9, 2026

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
Published on: December 18, 2016
A retrospective study of Ganoderma Lucidum Spore Powder for patients with epilepsy
Guo-Hui Wang1, Xin Li, Wen-Hui Cao
1First Ward of Neurology Department, First Affiliated Hospital of Jiamusi University, Jiamusi Second Ward of Neurology Department, Hongqi Affiliated Hospital of Mudanjiang Medical University, Mudanjiang Department of Physiology, Basic Medical College, Jiamusi University, Jiamusi, China.
Abstract:
This study firstly investigated the feasibility effect and safety of Ganoderma Lucidum Spore Powder (GLSP) for treating patients with epilepsy.Eighteen eligible patients with epilepsy were included. They all received GLSP treatment for a total of 8 weeks. The primary outcome included weekly seizure frequency. The secondary outcomes consisted of each seizure episode, and quality of life, measured by the Quality of Life in Epilepsy Inventory-31 (QOLIE-31), as well as the adverse events (AEs).After treatment, GLSP can significant reduce the weekly seizure frequency, compared with it before the treatment (P = .04). However, GLSP did not exert promising effect in each seizure episode (P = .13), and quality of life, measured by the QOLIE-31 scale (P = .11). Additionally, only minor AEs occurred during the treatment period.The results of this study showed that GLSP may be effective for reducing the weekly seizure frequency. Further studies are still needed to warrant this result.
More Related Videos
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Bioavailability Study Design: Healthy Subjects Versus Patients
Patient-centered Care
Drug Dosing: Geriatric Patients
Drug Dosing: Obese Patients
Case Studies

